News sentiment analysis powered by sentiment-insight.com
Lilly's Mounjaro leads to more and faster weight loss...
Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds. Within one year of starting treatment, 42.3% of those taking tirzepatide had lost at least 15% of their weight.
Weight loss drug maker plots ‘buy now, pay later’ offer Novo Nordisk is in talks to boost take-up of its Wegovy weight loss jabs. Chief executive Lars Fruergaard Jørgensen said it would spread out cost of treatments. He said innovative pricing deals would allow countries to “adopt medicines upfront, see the benefits and pay down the road”
Five hundred new jobs coming in Chartres, south of Paris Novo Nordisk will invest more than 15 billion Danish kroner (€2.1 billion) in an existing facility in Chartres, southwest of Paris. The Danish company has found that its Semaglutide medication, originally meant for diabetes, is also effective against obesity. Marketed as Wegovy in the United States, Denmark, Norway, and Germany, the drug helps chronically overweight patients.
Launches of Novo Nordisk's weight-loss drug Wegovy Wegovy was launched in the U.S. in June 2021 but it took Novo until December 2022 to make all doses available. The list price of four-week treatment is about $1,350, regardless of dosage.
Novo Nordisk ramps investments to boost Ozempic, Wegovy supply Novo Nordisk announced it will spend over $2.3 billion to expand a production facility in France. In the past two weeks, it's announced more than $8 billion in manufacturing investments. The firm makes Ozempic and Wegovy, two hit drugs that treat obesity.
Macron to unveil 2.1 bln eur Novo Nordisk pharma... French President Emmanuel Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France. The investment will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people.
Novo Nordisk spends big in France to expand obesity drug capacity Novo Nordisk will invest 2.1 billion euros ($2.3 billion) in an existing facility in Chartres, southwest of Paris. The Danish company has found that its Semaglutide medication, originally meant for diabetes, is also effective against obesity.
Novo Nordisk invests $2.3 mln in France to boost output Danish drug maker Novo Nordisk says it will invest more than 16 billion crowns ($2.34 billion) in the expansion of production facilities in Chartres in France. Europe's most valuable company by market value is fighting to keep up with soaring demand for anti-obesity drug Wegovy.
A new ETF will allow investors to cash in on the Ozempic-fueled weight loss craze that's swept markets this year The Tema Cardiovascular and Metabolic ETF (HRTS) made its stock market debut Tuesday on the Nasdaq. It holds positions in around 20 companies, including Novo Nordisk and Eli Lilly. Those shares have soared amid this year's frenzy for GLP-1 drugs.
Macron to unveil Novo Nordisk pharma investment in France French President Emmanuel Macron will on Thursday inaugurate a "major investment" by Danish pharmaceutical company Novo Nordisk. The investment will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people.
Novo Nordisk: Diabetes Drugs Shortages Will Persist Novo Nordisk will ration starter kits of Ozempic in Europe. The Danish drugmaker will reduce supplies of another diabetes drug, Victoza. The shortage of both would "deteriorate" during the remainder of this year, Novo warned.
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund The Tema Cardiovascular & Metabolic ETF invests in companies tackling diabetes, obesity and cardiovascular diseases. Shares in Eli Lilly and Novo Nordisk, which are among the fund's top holdings, have rallied 63% and 50% so far this year. Morgan Stanley Research expects the market for obesity drugs to surge to $77 billion in 2030.
Novo rations Ozempic starter kits in Europe amid surge in use for weight loss Ozempic contains semaglutide, an ingredient in Novo's hugely popular anti-obesity drug Wegovy. Ozempic is not officially approved to treat obesity, but that hasn't held back demand. The shortage of both would "deteriorate" during the remainder of this year, Novo warned.
Tema ETFs hops on weight-loss drug frenzy with its new... The Tema Cardiovascular & Metabolic ETF invests in companies tackling diabetes, obesity and cardiovascular diseases. Shares in Eli Lilly and Novo Nordisk, which are among the fund's top holdings, have rallied 63% and 50% so far this year.
EXPLAINER-What´s behind the scramble for semaglutide? Semaglutide, developed by Novo Nordisk over decades, is the active ingredient in type 2 diabetes treatments Ozempic and Rybelsus. Known as a glucagon-like peptide 1 (GLP-1) receptor agonist, it mimics a hormone produced in the gut that helps regulate blood sugar and appetite. More than 650 million people globally were estimated by the WHO to be obese in 2016.
What’s behind the scramble for semaglutide? Semaglutide, developed by Novo Nordisk over decades, is the active ingredient in type 2 diabetes treatments Ozempic and Rybelsus. It mimics a hormone produced in the gut that helps regulate blood sugar and appetite. Supply is not keeping pace with demand in countries including Britain, Germany, Belgium and the United States.
Pile the pounds ON your fund not your waist Danish pharmaceutical group Novo Nordisk has been boosted by the transformational impact of its diabetes and obesity drugs. AstraZeneca may also present an opportunity – its shares have tumbled by 13 per cent. But again Ben Ritchie, manager of the Dunedin Income Growth trust urges caution.
Investors increase holdings of weight-loss drug makers’ shares in Q3 -filings JPMorgan added more than 1.6 million in shares of Eli Lilly, worth roughly $1 billion. Some investors also bought more American Depositary Receipts of Novo Nordisk.
Global Ozempic shortage plagues Ontario diabetics and pharmacists | CBC News #Ozempic has reached more than 500 million views on TikTok. The drug is currently approved by Health Canada for the treatment of Type 2 diabetes. Manufacturer Novo Nordisk says it does not advertise Ozempic for weight loss.
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss Novo Nordisk shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend. Data presented on Saturday at a major medical meeting in the United States gave investors and analysts even more confidence in the cardiac benefits of Wegovy.
Sign Up
